BOT: Moving Forward, page-86

"Consistent with previous clinical studies, BTX 1503 was very well-tolerated. Adverse events were low across all treatment groups with the most commonly reported adverse event being upper respiratory tract infection (2.2% - 6.5%). Adverse events commonly seen with the use of topical acne products, application site stinging/ burning, itching (pruritus), pain, dryness, peeling and erythema were either absent or only observed in one or two patients. There were no severe adverse events reported and no treatment related discontinuations in the 5% BTX 1503 QD group. The very low incidence of application site adverse events supports the positioning of the Permetrex delivery technology as a safe and cosmetically elegant new formulation option for patients."

amateur apothecary thread -> LINK